Stay updated with breaking news from Bio Developments. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
We caught up with Kevin Knopp, CEO and co-founder of 908 Devices, to discuss the main obstacles in cell and gene therapy manufacturing and how the company's recent partnership with Terumo Blood and Cell Technologies is tackling these challenges.
WuXi AppTec has commissioned two new peptide manufacturing plants, one at its Changzhou facility and another at the new Taixing site in China.
Transgene and NEC are planning to extend their randomized phase 1 trial into a phase 2 study in 2024 to further demonstrate the potential of TG4050, a neoantigen vaccine for head and neck cancers.
AGC Biologics has announced plans to construct a new manufacturing facility at its existing Yokohama technical center in Japan.
Merck has announced a new licensing agreement with Inspirna for ompenaclid, a first-in-class treatment currently in phase 2 development for RAS-mutated (RASmut) advanced or metastatic colorectal cancer (mCRC).